Skip to main content

Table 2 The cumulative annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal using the Jacobs et al.[18] model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables Annual cost of operation Sharing rate # of HIV averted # of HCV averted HIV cost saved HCV cost saved Cost-effectiveness ratio HCV Cost-effectiveness ratio HIV Cost-benefit ratio HCV Cost-benefit ratio HIV
Post SIF $2,182,800 35% 14 84 $764,970 $769,212 $25,986 $155,914 1.35 1.35
Two SIF $4,365,600 28% 26 162 $1,108,830 $1,327,566 $26,948 $167,908 1.25 1.25
Three SIF $6,548,400 21% 32 195 $189,360 $304,485 $33,582 $204,637 1.03 1.03
Four SIF $8,731,200 18% 37 227 -$940,665 -$753,739 $38,463 $235,978 0.89 0.89
Five SIF $10,914,000 16% 43 261 -$1,860,135 -$1,741,677 $41,816 $253,814 0.83 0.83
Six SIF $13,096,800 13% 48 294 -$2,990,160 -$2,764,758 $44,547 $272,850 0.77 0.77
Seven SIF $15,279,600 10% 53 327 -$4,120,185 -$3,787,839 $46,727 $288,294 0.73 0.73
Average $8,731,200 7% 36 221 -$1,151,220 -$964,597 $39,508 $242,533 0.87 0.87